

PATHWAY TITLE

Treatment Pathway code:	WAHT-KD-023
Treatment Pathway Owner:	Elaine Stratford
<i>Job role</i> Cancer Quality Assurance manager	
Approved by:	Cancer Board
Date of Approval:	23 rd May 2019
Date of review:	23 rd May 2021

KEY DOCUMENTS TRANSFERRED INTO THIS PATHWAY

Key Document Name	Owner	Code	Version
Cancer Peer Review Policy	Anne Sullivan Vanessa Milner	WAHT-CS-002	12

AMENDMENTS MADE TO PATHWAY

Date	Amendments made	Approved by
9/3/17	Revert to original text in document in relation to referring to 'immediate risks' and 'serious concerns'.	Cancer Board

CONSULTATION

This Treatment pathway has been circulated to the following individuals for consultation

Name	Designation
Mr A Makar	Associate Medical Director Cancer Services
Sue Sharpe	Project Nurse Chemotherapy and Radiotherapy
Clare Hibbert	Cancer Data Manager
Laura Throssell	Assistant Cancer Data Manager
Cancer Board members circulated in papers in preparation for meeting 25/1/17	

MONITORING AND COMPLIANCE

This section should identify how the Trusts plan to monitor compliance with and the effectiveness of this Treatment pathway. It should include auditable standards and/or key performance indicators (KPIs) and details on the methods for monitoring compliance

What	How	Who	Where	When
<i>These are the 'key' parts of the process that we are relying on to manage risk.</i>	<i>What are we going to do to make sure the key parts of the process we have identified are being followed?</i>	<i>Who is responsible for the check?</i>	<i>Who will receive the monitoring results?</i>	<i>Set achievable frequencies.</i>
The pathway identifies a step by step process in relation to quality surveillance reviews of MDT's/services. It also clearly identifies all members of the team and their roles in the process.	This will be apparent at each review that is undertaken.	Cancer Quality Assurance Manager All members of the review panel	It will be discussed by the review panel and any changes made and approved at cancer board	Every quality surveillance internal validation.

EQUALITY IMPACT ASSESSMENT

To be completed by the Treatment pathway owner and submitted to the appropriate committee for consideration and approval.

		Yes/No
1.	Does the treatment pathway affect one group less or more favourably than another on the basis of:	
	Race	no
	Ethnic origins (including gypsies and travellers)	no
	Nationality	no
	Gender	no
	Culture	no
	Religion or belief	no
	Sexual Orientation	no
	Age	no
2.	Is there any evidence that some groups are affected differently?	no
3.	If you have identified potential discrimination, are any exceptions valid, legal and/or justifiable?	n/a
4.	Is the impact of the policy/guidance likely to be negative? If so can the impact be avoided?	n/a
5.	What alternatives are there to achieving the policy/guidance without the impact?	n/a
6.	Can we reduce the impact by taking different action?	n/a
7.	Other comments	

If you have identified a potential discriminatory impact of this key document, please refer it to Human Resources, together with any suggestions as to the action required to avoid/reduce this impact.

For advice in respect of answering the above questions, please contact Human Resources.

FINANCIAL IMPACT STATEMENT

To be completed by the Treatment pathway owner and submitted to the appropriate committee for consideration and approval.

		Yes/No
1.	Does the implementation of this document require any additional Capital resources	no
2.	Does the implementation of this document require additional revenue	no
3.	Does the implementation of this document require additional manpower	no
4.	Does the implementation of this document release any manpower costs through a change in practice	no
5.	Are there additional staff training costs associated with implementing this document which cannot be delivered through current training programmes or allocated training times for staff	no
6.	Other comments	

If the response to any of the above is yes, please complete a business case and which is signed by your Finance Manager and Directorate Manager for consideration by the Accountable Director before progressing to the relevant committee for approval